Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-101 in Advanced Malignant Tumors with NECTIN4 Gene Amplification
NCT07080619Phase 2Recruiting
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Allosteric Modulators, PROTACs (E3 ligase recruitment), Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of SC-101 in triple-negative breast cancer (TNBC), breast cancer (HR-positive/HER2-negative), solid tumor, sponsored by Tianjin ConjuStar Biologics Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
SC-101
03
Conditions
triple-negative breast cancer (TNBC)breast cancer (HR-positive/HER2-negative)solid tumor
Beyond the preview
Go deeper on NCT07080619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080619.